Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 115

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 115
---
 finalization of the post-closing true-up. Representations and Warranties The Divestiture Agreement contains representations and warranties of Aadi, Aadi Sub and Kaken. Some of the representations and warranties in the Divestiture Agreement made by Aadi and Aadi Sub are qualified as to “materiality,” “Seller Material Adverse Effect,” “Company Material Adverse Effect” or similar terms or concepts. For purposes of this proxy statement and the Divestiture Agreement, (1) “Seller Material Adverse Effect” means any change, event, effect, development or occurrence (“Effect”) that, individually or taken together with all other Effects, prevents or could reasonably be expected to prevent Aadi from consummating the Divestiture on or prior to 11:59 p.m. on June 30, 2025, or such later time and date as may be agreed among the parties under the terms of the Divestiture Agreement (the “Termination Date”) and (2) “Company Material Adverse Effect” means any Effect that, individually or taken together with all other Effects, (A) has had or would reasonably be expected to have a material adverse effect on the business, financial condition or results of operations of Aadi Sub, taken as a whole, or (B) prevents or would reasonably be expected to prevent Aadi Sub from consummating the Divestiture on or prior to the Termination Date. However, the parties have agreed that none of the following Effects will be deemed to be or constitute a Company Material Adverse Effect or will be taken into account when determining whether there has been or would reasonably be expected to occur a Company Material Adverse Effect:

| • |     | general economic conditions in the United States or any other country or region in the world, or changes in 
 conditions in the global economy generally (except in each case to the extent that such                     |

- 74 -

| Effect has had a disproportionate adverse effect on Aadi Sub relative to other similarly situated companies operating in the industries in which Aadi Sub conducts business, in which case only the                                               
 incremental disproportionate adverse impact of such Effect on Aadi Sub as compared to the impact of such Effect on such other similarly situated companies may be taken into account in determining whether a Company Material Adverse Effect has 
 occurred);                                                                                                                                                                                                                                        |

| • |     | conditions in the financial markets, credit markets or capital markets in the United States or any other country                                                                                                                                          
 or region in the world, including (1) monetary